

Type of Article: Review

TITLE: ROLE OF CATHEPSIN IN ORAL DISEASE – A review

Authors:

¹Dr. Lalli Dharmarajan, ²Dr. E.P. Sridevi Anjuga, ³Dr. Pradeep P Elango, ⁴Dr. N. Aravindha Babu MDS

Molecular biologist, Centre for Oral Cancer Prevention Awareness and Research, Sree Balaji Dental College & Hospital, Chennai. BIHER

Post Graduate student, Department of Oral pathology & Microbiology, Sree Balaji Dental College and Hospital, Chennai. BIHER.

Assistant Professor, Dental Department, Dhanalakshmi Srinivasan Medical College and Hospital.

Professor, Department of Oral Pathology & Microbiology, Sree Balaji Dental College & Hospital, Chennai, BIHER

ROLE OF CATHEPSIN IN ORAL DISEASES – A REVIEW:

ABSTRACT:

Cathepsins are a class of globular lysosomal proteases that are known to be responsible for protein degradation. They have many biological roles besides proteolysis, such as apoptosis wound healing angiogenesis, proenzymatic activation, bone remodeling, and resorption. The role of cathepsins in pathogenesizing systemic diseases such as cancer, bronchial asthma, atherosclerosis, neurological disorders, rheumatoid arthritis and osteoarthritis has been involved. This review emphasizes the role of cathepsins in multiple oral diseases such as periodontitis, odontogenic cysts, ameloblastoma, tumors of the salivary glands and malignant melanoma.

KEYWORDS: *Cathepsin, Oral disease, Proteases, cancer*

1. INTRODUCTION:

Proteases are the type of enzymes that catalyze hydrolysis of peptide bonds and aid in the digestion of proteins. These enzymes are pervasive in nature, and control many biological processes¹. They control blood clotting, cell proliferation, angiogenesis, wound repair, necrosis, and apoptosis¹. There are 84 families of proteases that are categorized by their catalytic activity into serine, aspartic, cysteine, and metalloproteases¹. The name cathepsin, which is derived from the Greek kathepsin (to digest), was proposed for the protease that was active in a slightly acidic environment². Later, Rich Willstaetter and Eugen Bamann proposed the terminology "cathepsin" in 1929 to describe the tissue proteolytic activity of leucocytes at a slightly acidic pH¹. Cathepsins are graded as:

1. Serine proteases: cathepsins A and G;
2. Aspartic proteases: D and E cathepsins; and lysosomal cysteine cathepsin
3. There are 11 human cysteine cathepsins, i.e., the cathepsins B, C, F, H, K, L, O, S, V, X and W, existing at the sequence level; this was confirmed by a bioinformatic analysis of the draft sequence of the human genome².

Such enzymes play a key role in multiple physiological processes such as apoptosis, antigen presentation, activation of proenzymes, wound healing, bone remodeling, neuropeptide, and storage of hormones¹. The expression of cathepsins is regulated by endogenous inhibitors such as cystatins, serpins, and thyroptins to preserve tissue homeostasis². The release of inactive cathepsins and the presence of endogenous inhibitors help to maintain physiological equilibrium¹. Numerous ailments such as atherosclerosis, osteoporosis,

arthritis, neurological disorders and cancer have been connected with their dysregulation¹. Cathepsins are also produced by pathogenic bacteria which act as virulence factor and result in development of diseases¹.

2. STRUCTURE OF CATHEPSIN:

The crystal structure of papain, a cysteine protease from *Carica papaya*, was among the first dozen protein crystal structures to be determined. Together with actinidin, these two structures provided the first insight into their three-dimensional (3D) structure. Later developments enabled the isolation of cysteine cathepsins, such as cathepsin B, H, L, S, X, C, from various tissues, while the rest of the cathepsins were expressed in various expression systems².

3. CATHEPSIN STRUCTURE ACTIVATION AND INHIBITION:

The cathepsins are produced as inactive zymogen; the prodomain found in zymogen blocks the active sites, preventing hydrolysis of the substrates³. Zymogen change is necessary for activation, in which the prodomain is removed³. The signal peptide present in inactive state is cleared inside the endoplasmic reticulum and these proenzymes are glycosylated, which are then carried to Golgi apparatus². Phosphorylation of mannose residues occurs in Golgi apparatus, and mannose 6 phosphate is produced which reaches lysosomes through mannose 6 receptor pathway³. Acidification occurs in late endosome resulting in disassociation of prodomain from active site and becoming active in cathepsins³. Therefore, Prodomain serves as an autoinhibitor for cathepsins³. The entire activation takes place through autocatalytic or transactivation mechanisms in the lysosomes³. Activation process is enhanced by acidic condition and presence of glycosaminoglycans. Proteolytic activation is mediated by metalloproteinases in the matrix³. Cathepsin activity can be controlled mainly by distortion and blockage of active site by inhibition¹. Endogenous inhibitors including cystatins, thyropins, and serpins suppress cathepsin¹. Cystatins form the largest group of endogenous cathepsin inhibitors that primarily target cysteine proteases⁴. Intracellular cystatins inhibit cysteine proteases by slightly blocking the active center by noncovalent interaction⁴.

The cystatine family is further divided into:

- cystatin type 1 (stefins),
- cystatin type 2 (cystatins), and
- cystatin type 3 (kinogens).

The serpins can inhibit serine proteases and cysteine proteases⁴. Its inhibitory mechanism is by active site degradation⁴. Thyropins suppress the proteases in cysteine. There are no known endogenous aspartate protease inhibitors till date⁴.

4. CATHEPSIN LOCALIZATION AND FUNCTION:

CATHEPSIN B:

Cathepsin B is the first identified member of what has become known as the broad family of lysosomal cysteine peptidases⁵. This is the most widely expressed cathepsin encoded by the CTSB gene mapped by chromosome 8p22¹. It is present at high levels in gingival crevicular fluid and macrophages¹. Cathepsin B was immuno-localized to granular duct cells and gingival fibroblasts in the submandibular gland¹. This is active primarily in cellular processes such as proteolysis, antigen synthesis, and apoptosis¹. Cathepsin B is an essential activator of trypsin in acute pancreatitis³. It also causes collagen degradation and other non-collagenous matrix proteins, and thus plays a key role in resorption lacunae formation in deciduous teeth⁶. It can be seen in the human dentin- pulp complex¹. Cathepsin B was identified also in ameloblasts¹.

CATHEPSIN C:

Cathepsin C (CTSC), also known as dipeptidyl peptidase I, is encoded by the CTSC gene located on chromosome 11q14⁷. It is an exogenous salivary peptidase that extracts dipeptides away from N-terminals peptides⁷. In inflammatory cells, it plays a major role in activating platelet factor XIII and various serine proteases⁷. Increased levels of enzymatically active serine-cysteine cathepsin-C were expressed by dermal / stromal fibroblasts and bone marrow-derived cells, which controlled the complexity of infiltrating immune cells in neoplastic skin, angiogenic vasculature development and overt squamous cell carcinoma growth⁸.

CATHEPSIN D:

Cathepsin-D is a proteinase that induces collagenolytic activity, resorption of the bone and is closely involved in tumor progression biological process⁹. Cathepsin-D was present in many normal tissues, including epithelium, fibroblast, and macrophages⁹. Cathepsin-D's physiological function is thought to be involved in the self-destruction of senescent or weakened epithelial cells⁹. Cathepsin D is involved in protein, polypeptide hormone and growth factor metabolic degradation¹⁰. It functions as mitogen in many epithelial tissues and helps in remodeling and renewal of tissue¹⁰. It is present in the gingival fluid in the oral cavity and immuno-located in rat junctional epithelium and oral mucosa¹⁰.

CATHEPSIN G:

It is mainly formed by neutrophils and plays an important role in the elimination of intracellular pathogens and the breakdown of tissues at inflammatory sites¹. In addition, it is involved in platelet activation that leads to platelet aggregation and formation of clots¹. CTSG has been found in other myeloid cells, such as B cells, primary human monocytes, dendritic myeloid cells, dendritic plasmacytoid cells and murine microglia¹¹. Cathepsin G has a number of functions. It can clear pathogens, regulate inflammation, stabilise blood pressure, and induce thrombogenesis by altering chemokines, cytokines, cell surface receptors and C components¹¹. The concentration and activity of CTSG are increased in the synovial fluids of rheumatoid arthritis (RA) patients¹¹.

CATHEPSIN K:

This protein, a part of lysosomal cysteine proteases, mainly expressed in osteoclasts and is involved in bone remodelling and resorption. It can break down bone and cartilage through its catabolic action¹. Cathepsin K found in the odontoclasts in the deciduous tooth is responsible for the extracellular degradation of dentin collagen during physiological root resorption¹. In rheumatoid arthritis joints, cathepsin K is strongly expressed in osteoclasts, in most epithelial cells, and in synovial fibroblasts². Cathepsin K is the only enzyme that has been unambiguously recorded in mice and humans to play an important role in bone resorption². Cathepsin K was also highly displayed in patients suffering from ankylosing spondylitis at bone destruction sites¹¹. Cathepsin K contributes both to the erosion of the blood vessels and to plaque destabilization¹². Cathepsin K inhibitors are useful tools for adipogenesis and analyse the role of cathepsin K in obesity, and may represent potential for future treatment¹². Cathepsin K has also been suspected in pathogenesis of osteoarthritis¹². In addition to its expression in breast, lung, melanoma and thyroid cancers, cathepsin K has also been associated with increased invasive potential in prostate tumours¹².

CATHEPSIN L:

Cathepsin L is implicated in the cleavage of a broad variety of compounds, such as fibronectin, collagen and laminin, including the extracellular matrix¹⁰. Cathepsin L is believed to be involved in intracellular or endocytosed protein turnover, antigen processing and presentation, bone resorption, and various other processes¹⁰.

CATHEPSIN S:

Importantly, cathepsin S is expressed in professional antigen-presenting cells (APCs), such as dendritic cells (DCs) and B-cells². It is a lysosomal cysteine protease capable of degrading extracellular matrix components, such as collagen, elastin, fibronectin, laminin, and proteoglycans, which indicate a pivotal role in homeostasis and repair of tissue¹³. Cathepsin S facilitates cell migration and also controls differentiation of osteoblasts and remodelling of bones¹³. Cathepsin S has been widely involved in health and pathology including including autoimmune disorders, allergic inflammation and asthma, diabetes and obesity, cardiovascular and respiratory disorders, as well as cancer¹³.

CATHEPSIN W:

Cathepsin W is mainly found in CD8 + lymphocytes and natural killer (NK) cells².

CATHEPSIN L:

Cathepsin L variants localized to the nucleus play a role in the regulation of cell-cycle progression². Cathepsin L involved in transduction of cardiac signal³.

CATHEPSIN V:

- Cathepsin V (also called L2) is strongly homologous to cathepsin L but its expression is limited to thymus and testis in contrast to the omnipresent cathepsin L². Specific expression of cathepsin V in human thymic cortical epithelial cells¹⁴. In stenotic aortic valves and atherosclerotic plaques, the expression of cathepsin V is increased, indicating a role in the degradation of elastin laminae in diseased blood vessels¹⁴. Cathepsin V was considered a possible diagnostic marker for colon tumours which was identified as an antigen in breast cancer patients¹⁴.
- In patients with multiple sclerosis, the expression and activity of cathepsin B, cathepsin D, and cathepsin S was increased and correlated with the physiological degradation of myelin basic protein¹¹.
- Cathepsin B and Cathepsin S also had a potential role in the pathology of grave's disease and myasthenia gravis¹¹.

5. CATHEPSIN IN ORAL DISEASES:

DENTAL CARIES:

- Dental caries is a microbial disease caused by demineralization of inorganic and dissolution of organic matrix¹. MMPs are primarily involved in the pathogenesis of caries¹. Cysteine cathepsins are colocalized and thought to activate the latent MMPs and facilitate the development of caries with MMPs¹. Compared to sound dentin, cathepsin B demonstrated greater immunoreactivity in carious dentin¹. Cathepsin B levels were associated with rising depth in carious dentin¹. In the dentinal fluid, MMP-20, MMP-2, and probably also cathepsin B are present and can contribute to the lesion activity in areas with large dentinal tubules¹⁵.

PERIAPICAL LESIONS:

- As a sequelae of pulpal inflammation periapical lesions form around the tooth apex¹. They manifest as a result of host immune response against bacteria. It may result in resorption of hard tissues and destruction of periapical tissues¹. Often, some inflamed tissue factors may contribute to the failure of endodontic therapy¹. Osteoclasts play a key role in deteriorating the bone matrix in periapical lesions¹. Cathepsin K is primarily expressed in osteoclasts and involved in bone remodelling and resorption¹². Cathepsin K was a vital bone-resorbing protease and the race for the treatment of osteoporosis was to produce highly selective cathepsin K inhibitors¹².

ORAL LICHEN PLANUS:

- Oral lichen planus is a chronic T-cell- mediated mucosal disease. In psoriasis, cathepsins K inhibitor has shown to inhibit TLR-mediated cytokine by dendritic cells¹⁶. TLR4 and TLR9 induction occur in oral lichen planus, and co-expression of cathepsin K has been seen in some dendritic cells¹⁶. It is therefore proposed that in oral lichen planus, cathepsin K is involved in dendritic cell upregulation of the activity of cytokines¹⁶. In OLP lesions, epithelial cells under the influence of the underlying stromal proteases of the connective tissue, secreted by the inflammatory cells stained by Cathepsin B, are more likely to turn into cancer cells¹⁷.

PERI-IMPLANTITIS:

- The peri-implantitis inflammatory process affects the tissues surrounding dental implants, sometimes contributing to implant failure¹. Yamalik et al . noted that cathepsin K operating levels are higher in peri-implantitis and peri-mucositis compared to healthy peri-implant tissues¹. Increased RANKL expression stimulated the formation of active osteoclasts leading to increased cathepsin K development leading to bone resorption¹.

PERIODONTITIS:

- Periodontitis is a chronic inflammatory disease that is highly prevalent and is characterised by bone, attachment, and even tooth loss¹³. Cathepsin S expressed in periodontitis stimulates the proliferation and migration of PDL cells and thus wound closure, suggesting that this cysteine protease may play a critical role in the healing and periodontal remodelling¹³. Another member of the cathepsin family, Cathepsin K was also associated with periodontal diseases¹³. Cathepsin S is interestingly capable of degrading Cathepsin K, suggesting complex interactions between both cathepsins¹³.
- Cathepsin G also showed increased involvement in adults periodontitis¹⁸. Through proteolytic activation of latent neutrophil procollagenase (promatrix metalloproteinase 8), this enzyme may break down periodontal tissues directly and indirectly and can contribute to periodontitis¹⁸. As these enzymes correlate with pocket depth, they can serve as biomarkers of periodontal inflammation¹⁸.

6. PAPILLON – LEFEVRE SYNDROME:

It is an autosomal recessive disorder characterised by severe early-onset periodontitis and palmoplantar hyperkeratosis that results in premature loss of teeth. This condition is responsible for mutations within the CTSC gene¹. CTSC plays a predominant role in phagocytosis¹. Immunological findings such as reduced neutrophil, monocyte chemotaxis, impaired phagocytosis, and altered superoxide production are noted in patients affected by this syndrome¹. The cell ability of polymorphonuclear leukocyte (PMNL) does not remove the *Aggregatibacter actinomycetemcomitans* that result in periodontitis¹.

GIANT CELL TUMORS:

- The giant cell tumour is a benign bone neoplasm marked by localised osteolysis¹. Cathepsin K is detected exclusively in osteoclast-like giant cells in giant cell tumours which support the hypothesis that it is the predominant factor in osteolysis¹. Cathepsin K staining patterns were large in giant cell lesions in 85% of peripheral giant cell granulomas, 60% of giant cell tumours, and 57% of core giant cell granulomas¹. Cathepsin L is other protease present in giant cell lesions and tumors¹. Cathepsin D plays a role in numerous physiological and pathological procedures, including bone resorption¹⁹. Cathepsin D has been observed in the giant cells of both CGCG and PGCG lesions¹⁹. The osteoclastic origin of giant cells in both PGCG and CGCG could be confirmed by the expression of Cathepsin D in giant cells, which is considered a factor involved in bone degradation and one of the enzymes present in osteoclasts¹⁹.
- Cathepsin D plays an indirect role in the degradation of the bone matrix through activation of Cathepsin B and L in osteoclasts¹⁹. Therefore, a higher Cathepsin D concentration in CGCG giant cells may be considered as a factor in developing more active Cathepsin B and L, and therefore more degradation of the bone¹⁹. Active cathepsin B and L will prevent further osteolytic activity in the lesion¹⁹.

ODONTOGENIC CYSTS AND TUMORS:

- The staining intensity of cathepsin D between various odontogenic cysts was observed in each layer and stroma / capsular wall¹. In the epithelial lining and stroma, different staining patterns were observed. The staining severity increased gradually from the dentigerous cyst to the odontogenic keratocyst (OKC) via the radicular cyst¹. This increasing pattern of expression seemed to correlate with increasing aggression¹. Intense granular staining has been found in OKC's separation region. This finding indicates that cathepsin B may be one of the essential enzymes in epithelium and connective tissue separation in OKC¹. Marked staining of the granular cells and spillage in granular cell ameloblastoma compared with others may explain its aggressive behaviour, recurrence, and metastatic potential¹.
- Cathepsin-D is a proteinase that induces collagenolytic activity, bone resorption and is closely involved in the biological tumour progression process that has been documented to be an indicator of aggressive behaviour in human tumours, including oral squamous cell carcinoma, due to its ability to digest the extracellular matrix⁹ It is suspected that cathepsin-D physiological function is involved in the self-destruction of senescent or weakened epithelial cells⁹.
- Cathepsin D is expressed in the epithelium, connective tissue and stromal cells of odontogenic cyst and tumors⁹.

SALIVARY GLAND TUMORS:

- Among head and neck tumours, salivary gland tumours are histologically the most heterogeneous tumours. Higher expression of cathepsin D in neoplasms with malignant salivary gland compared to benign tumours. Intense expression of cathepsin D was observed in mucoepidermoid carcinoma and adenoid cystic carcinoma when compared to pleomorphic adenoma, indicating that it was a marker of invasive potential and aggressive behavior²⁰.

SJOGREN'S SYNDROME:

- Cathepsin B, cathepsin D, and cathepsin S were present in Sjögren's syndrome and had greater immunoreactivity in patient's acini and tears¹¹. The cathepsin S inhibitor was effective in the prevention of salivary and lacrimal autoimmune lesions in patients with Sjögren's syndrome¹¹.

ORAL CANCER:

- Cancer is a multi-stage phase involving genetically altered changes. Diverse proteases monitor the invasiveness and metastasis. Cathepsins degrade the extracellular matrix and thus interrupt intercellular communication.
- Cathepsin B can contribute to uncontrollable proteolysis and participate in the process of tumor development, invasion, and metastasis in dissolution and remodeling of the connective tissue and basement membrane¹. The expression of Cathepsin B was associated with positive lymph node metastasis and a higher tumor grade, thereby indicating its role in malignant tongue cancer progression¹.
- On the other hand, although Cathepsin C is up-regulated during carcinogenesis of the pancreatic islet, it lacks functional significance in mediating neoplastic progression in that organ⁸. Since the expression and enzymatic activity of both of both Cathepsin B and Cathepsin C are raised in various tumors⁸. Increased levels of enzymatically active Cathepsin C were expressed by dermal / stromal fibroblasts and bone marrow-derived cells, which regulated the complexity of infiltrating immune cells in neoplastic skin, angiogenic vasculature formation, and overt squamous cell carcinoma growth⁸.
- The expression of cathepsin D was observed during the conversion of dysplasia to oral squamous cell carcinoma¹⁷. The expression associated with invasiveness and progression of cancer. The origin of cathepsin D from the lysosome to the invasive front of the tumour is altered and its expression is associated with abnormalities of the p53 gene¹⁷. Cancer cells also secrete procathepsin D that acts as a metastases and mitogen stimulating proinvasion¹⁷.
- Majority of cancers including a few dysplastic areas surrounding carcinoma tissue, cathepsin K was found in OTSCC patient samples²¹. In the morphologically normal-looking tongue epithelium, we were not able to detect cathepsin K²¹. Cathepsin K was present in carcinomas, as well as stromal cells²¹.
- Overexpression of cathepsin L is more likely to lead to progression of tumor in oral cancer¹. Cathepsin L expression associated with metastasis of the lymph node and poor prognosis, indicating its function as a potent biomarker for cancer prognosis¹.

4. CONCLUSION:

Cathepsins play a vital role in pathogenesis of both systemic and oral diseases. They can act as biomarkers in various oral diseases. Future research and investigation is needed to have a clear idea about the correct pathogenesis of cathepsins in oral diseases.

5. REFERENCE:

- [1] Benarji KA, Lakshmi KR, Nelakurthi H, Haritha P, Amrutha R. Cathepsins in oral diseases. Journal of Dr. NTR University of Health Sciences. 2019 Jul 1;8(3):153.
- [2] Turk V, Stoka V, Vasiljeva O, Renko M, Sun T, Turk B, Turk D. Cysteine cathepsins: from structure, function and regulation to new frontiers. *Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics*. 2012 Jan 1;1824(1):68-88.
- [3] Jedeszko C, Sloane BF. Cysteine cathepsins in human cancer. *Biological chemistry*. 2004 Nov 1;385(11):1017-27.

- [4] Kos J, Lah T. Role of cystatins and stefins in cancer. In: Zerovnik E, Kopitar-Jerala N, Uversky V, editors. *Human Stefins and Cystatins*. New York, NY: Nova Science Publishers, Inc; 2006. p. 233-6.
- [5] Mort JS. Chapter 406-Cathepsin B. *Handbook of Proteolytic Enzymes (Third Edition)*; Rawlings, ND, Salvesen, G., Eds. 2013:1784-91.
- [6] Sasaki T, Ueno-Matsuda E. Immunocytochemical localization of Cathepsins B and G in odontoclasts of human deciduous teeth. *J Dent Res* 1992;71:1881-4.
- [7] Pham CT, Ley TJ. Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. *Proc Natl Acad Sci USA* 1999;96:8627-32
- [8] Ruffell B, Affara NI, Cottone L, Junankar S, Johansson M, DeNardo DG, Korets L, Reinheckel T, Sloane BF, Bogyo M, Coussens LM. Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. *Genes & development*. 2013 Oct 1;27(19):2086-98.
- [9] Lakkasetty Y, Venkatraman N, Shivamalappa SM. The expression of cathepsin-D in odontogenic cysts and tumors: Immunohistochemistry study. *Journal of Advanced Clinical and Research Insights*. 2015 Mar 1;2(2):67-71.
- [10] Lah T, Skallrič U, Babnik J, Turk V. Detection of cathepsin L-like proteinase and cathepsin D in gingival fluid. *Journal of Periodontal Research*. 1986 Sep;21(5):504-9.
- [11] Siming GA, Honglin ZH, Xiaoxia ZU, Hui LU. Cathepsin G and its role in inflammation and autoimmune diseases. *Archives of rheumatology*. 2018 Dec;33(4):498.
- [12] Brömme D, Lecaille F. Cathepsin K inhibitors for osteoporosis and potential off-target effects. *Expert opinion on investigational drugs*. 2009 May 1;18(5):585-600.
- [13] Memmert S, Nokhbehshaim M, Damanaki A, Nogueira AV, Papadopoulou AK, Piperi C, Basdra EK, Rath-Deschner B, Götz W, Cirelli JA, Jäger A. Role of cathepsin S In periodontal wound healing— an in vitro study on human PDL cells. *BMC oral health*. 2018 Dec;18(1):1-7.
- [14] Neil D, Rawlings ND, Salvesen G. *Handbook of proteolytic enzymes*.
- [15] Nascimento FD, Minciotti CL, Geraldeli S, Carrilho MR, Pashley DH, Tay FR, Nader HB, Salo T, Tjäderhane L, Tersariol IL. Cysteine cathepsins in human carious dentin. *Journal of dental research*. 2011 Apr;90(4):506-11.
- [16] Siponen M, Bitu CC, Al-Samadi A, Nieminen P, Salo T. Cathepsin K expression is increased in oral lichen planus. *J Oral Pathol Med* 2016;45:758-65.
- [17] Satelur KP, Bopaiah S, Bavle RM, Ramachandra P. Role of Cathepsin B as a Marker of Malignant Transformation in Oral Lichen Planus: An Immunohistochemical Study. *Journal of clinical and diagnostic research: JCDR*. 2017 Aug;11(8):ZC29.
- [18] Pushparani DS, Nirmala S. Cathepsin D level in the human gingival tissues and serum of periodontitis patients. *Int J Pharma Sci Res* 2014;5:1924-30.
- [19] Zargar M, Moghimbeigi A, Afsharmoghadam N, Isfahani MN, Hashemi A. A comparative study of cathepsin D expression in peripheral and central giant cell granuloma of the jaws by immunohistochemistry technique. *Journal of Dentistry*. 2016 Jun;17(2):98.
- [20] Vigneswaran N, Muller S, Derosé P, Cohen C. Cathepsin-D and tumor associated antigen DF3 in salivary gland neoplasia. Differential diagnostic and prognostic applications. *Pathol Res Pract* 1994;190:1174-84.
- [21] Bitu CC, Kauppila JH, Bufalino A, Nurmenniemi S, Teppo S, Keinänen M, Vilen ST, Lehenkari P, Nyberg P, Coletta RD, Salo T. Cathepsin K is present in invasive oral tongue squamous cell carcinoma in vivo and in vitro. *PLoS One*. 2013 Aug 7;8(8):e70925.